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2106(PCV13). Enrolled infants (6–14 weeks old) were born to mothers who were randomized to receive
reduced-antigen-content diphtheria-tetanus-three-component acellular pertussis vaccine (Tdap group)
or placebo (control group) during pregnancy (270/7–366/7 weeks’ gestation) with crossover immunization
postpartum. All infants received 2 or 3 DTaP-HepB-IPV/Hib and PCV13 doses according to national sched-
ules. Immunogenicity was assessed in infants pre- and 1 month post-primary vaccination. The primary
objective was to assess seroprotection/vaccine response rates for DTaP-HepB-IPV/Hib antigens 1 month
post-primary vaccination.
Results: 601 infants (Tdap group: 296; control group: 305) were vaccinated. One month post-priming,
seroprotection rates were 100% (diphtheria; tetanus), 98.5% (hepatitis B), 95.9% (polio) and 94.5%
(Hib) in both groups. Vaccine response rates for pertussis antigens were significantly lower in infants
whose mothers received pregnancy Tdap (37.5–77.1%) versus placebo (90.0–99.2%). Solicited and unso-
licited adverse event rates were similar between groups. Serious adverse events occurred in 2.4% (Tdap
group) and 5.6% (control group) of infants, none were vaccination-related.
Conclusions: Pertussis antibodies transferred during pregnancy may decrease the risk of pertussis infec-
tion in the first months of life but interfere with the infant’s ability to produce pertussis antibodies, the
clinical significance of which remains unknown. Safety and reactogenicity results were consistent with
previous experience.
Clinical Trial Registration: ClinicalTrials.gov: NCT02422264.
 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Despite comprehensive global infant immunization programs,
pertussis (Bordetella pertussis) continues to cause high morbidity
and mortality among infants <2 months of age who are too young
to be vaccinated [1,2]. Several strategies to optimize pertussis con-
trol and protection during this susceptible period were pursued
[3]; vaccination of pregnant women is the most commonly
implemented.
Randomized controlled trials (RCTs) and prospective cohort
studies have provided evidence that adult-formulation
diphtheria-tetanus-acellular pertussis (Tdap) immunization during
the second or third trimester of pregnancy results in high levels of
pertussis antibodies in cord blood [4–10].
This maternal immunization strategy has been observed to pro-
vide 69%–93% effectiveness against pertussis disease in the first 2
or 3 months of life [11–19]. However, several studies have raised
concerns that transplacentally acquired antibodies could interfere
with the infant’s immune response to pertussis and other antigens
in the primary infant series (i.e., immunological interference or
blunting) [4–8,10,20–23]. We evaluated the immunogenicity and
safety of a childhood hexavalent diphtheria-tetanus-three-compo
nent acellular pertussis-hepatitis B virus-poliovirus and Hae-
mophilus influenzae type b-tetanus toxoid conjugate vaccine
(DTaP-HepB-IPV/Hib) co-administered with the 13-valent pneu-
mococcal conjugate vaccine (PCV13) in infants born to mothers
given reduced-antigen-content Tdap vaccine during pregnancy or
postpartum.2. Methods
2.1. Study design and participants
This phase IV, multi-center, open-label, non-randomized trial
with two parallel groups was conducted between 22 January
2016 and 7 March 2018 in Australia, Canada, Czech Republic, Fin-
land, Italy and Spain. The trial (ClinicalTrials.gov: NCT02422264)
was performed according to the principles of Good Clinical Prac-
tice, the Declaration of Helsinki and applicable regulations. The
centers’ Institutional Review Boards and/or Ethics Committees
(Supplementary material) approved the protocol, informed con-
sent form and other study-related documents. An independent
data monitoring committee oversaw the participants’ safety.We enrolled healthy infants 6–14 weeks old whose mothers
had participated in a phase IV, observer-blind, randomized,
placebo-controlled maternal immunization trial (NCT02377349)
in which they received reduced-antigen-content Tdap vaccine or
placebo at 270/7–366/7 weeks’ gestation and crossover administra-
tion within 72 h postpartum [24]. Infants born prematurely
(<37 weeks’ gestation, but after 27 weeks’ gestation) could be
enrolled if they were medically stable. Exclusion criteria included
a history of diphtheria, tetanus, pertussis, hepatitis B, polio, Hib
or pneumococcal diseases; vaccination against any of these dis-
eases since birth (except hepatitis B vaccination); administration
of long-acting immune-modifying drugs, any chronic drug therapy
or immunoglobulins and/or blood products; and immunosuppres-
sive conditions. The Supplementary methods provide detailed
inclusion and exclusion criteria. The parent(s) or legally acceptable
representative(s) of each participant provided written informed
consent before enrollment.
The infants’ group allocationwas determinedby the intervention
their mothers received during pregnancy (Tdap or placebo) in the
maternal immunization trial [24]. The study had an open-label
design because all infants received the same vaccines, but investiga-
tors and study staff involved in the infants’ care and responsible for
evaluating the study endpoints and laboratory testing remained
blinded to the treatment allocation of the infants’ mothers.2.2. Procedures
Infants received 2 or 3 doses of DTaP-HepB-IPV/Hib (Infanrix
Hexa, GSK) co-administered with PCV13 (Prevnar 13, Pfizer Inc.)
at 2 and 4 months; or 3 and 5 months; or 2, 4 and 6 months; or
2, 3 and 4 months of age, according to the different countries’ rou-
tine primary immunization schedules (Fig. 1). In some countries/
regions with a 3-dose primary DTaP-HepB-IPV/Hib schedule,
PCV13 was given as a 2-dose schedule at 2 and 4 months of age.
DTaP-HepB-IPV/Hib and PCV13 were injected intramuscularly in
opposite thighs. PCV13 contains capsular polysaccharides of 13
pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A,
19F and 23), each conjugated to the diphtheria toxoid variant
CRM197. The composition of both vaccines is provided in the Sup-
plementary methods.
Blood samples were collected before the first DTaP-HepB-IPV/
Hib dose (2 mL, pre-primary) and 1 month (allowed interval: 21–
48 days) after the last DTaP-HepB-IPV/Hib dose (5 mL, post-
Fig. 1. Study design. Abbreviations: DTaP-HepB-IPV/Hib, diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated poliovirus and Haemophilus influenzae type b
vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; Tdap, reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine. a2-dose DTaP-HepB-IPV/Hib
primary schedule at 2 and 4 months of age administered in Spain. b2-dose DTaP-HepB-IPV/Hib primary schedule at 3 and 5 months of age administered in Finland and Italy.
cOnly for infants receiving a 3-dose DTaP-HepB-IPV/Hib primary schedule. Infants who received a 2-dose DTaP-HepB-IPV/Hib primary schedule did not attend visit 3. d3-dose
DTaP-HepB-IPV/Hib primary schedule at 2, 3 and 4 months of age administered in Czechia. e3-dose DTaP-HepB-IPV/Hib primary schedule at 2, 4 and 6 months of age
administered in Australia, Canada and Spain. fPCV13 was co-administered as a 2-dose or 3-dose primary vaccination schedule; in some countries, infants received a 3-dose
DTaP-HepB-IPV/Hib schedule but a 2-dose PCV13 schedule (at 2 and 4 months of age).
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three pertussis antigens (filamentous hemagglutinin [FHA], per-
tactin [PRN] and pertussis toxoid [PT]) were measured using vali-
dated enzyme-linked immunosorbent assays (ELISAs), with assay
cut-offs (lower limits of quantitation [LLoQs]) of 0.057 IU/mL
(anti-diphtheria), 0.043 IU/mL (anti-tetanus), 2.046 IU/mL (anti-
FHA), 2.187 IU/mL (anti-PRN) and 2.693 IU/mL (anti-PT) defining
seropositivity. Seroprotection for diphtheria and tetanus was
defined as an antibody concentration0.1 IU/mL [25,26]. No corre-
late of protection has been established for pertussis [27]. Anti-
hepatitis B surface antigen (HBs) antibodies were measured using
a commercial chemiluminescence immunoassay (ADVIA Centaur
anti-HBs2, Siemens Healthcare) with an assay cut-off of 6.2 mIU/
mL and a concentration of 10 mIU/mL defining seroprotection
[27–29]. Anti-poliovirus types 1, 2 and 3 antibodies were mea-
sured using a validated microneutralization test [30], with anti-
body titers 8 considered protective. Anti-Hib polyribosylribitol
phosphate (PRP) antibodies were measured using a validated
ELISA, with an assay cut-off of 0.066 mg/mL and concentrations of
0.15 mg/mL and 1.0 mg/mL indicative of short- and long-term pro-
tection, respectively [31,32]. Serotype-specific anti-pneumococcal
capsular polysaccharide antibodies (for the PCV13 serotypes) were
measured using validated multiplex electrochemiluminescence
(ECL) assays [33]. A threshold of 0.35 mg/mL for the ECL assays
was shown to be equivalent to the 0.35 mg/mL PCV licensure
threshold established for the World Health Organization pneumo-
coccal reference ELISA [33,34]. All assays were performed at GSK,
Rixensart/Wavre, Belgium.
At each vaccination visit, the infants’ parents or legally accept-
able representatives (LARs) received diary cards to record solicited
local (injection site pain, redness, swelling) and general (drowsi-
ness, irritability, loss of appetite, fever) adverse events (AEs) within
4 days and unsolicited AEs within 31 days after each vaccination.
Diary cards were returned at the next visit, during which the inves-
tigators asked the parents/LARs about any other possible AEs (or
serious AEs [SAEs]) occurring since the previous visit. SAEs were
collected from the first DTaP-HepB-IPV/Hib dose until study end.
The total safety follow-up time depended on the vaccination
schedule: approximately 5 months for infants receiving a 3-dose
schedule at 2, 4 and 6 months of age and approximately 3 months
for infants receiving the other schedules. The investigators
assessed the intensity of all AEs and their causal relation to infant
vaccination. Solicited local AEs were all considered vaccination-
related.2.3. Objectives
The primary objective was to assess the immune response to
DTaP-HepB-IPV/Hib in terms of anti-diphtheria, anti-tetanus,
anti-HBs, anti-poliovirus types 1–3 and anti-PRP seroprotection;
and anti-FHA, anti-PRN and anti-PT vaccine responses 1 month
post-primary vaccination. Vaccine response was defined as a
post-vaccination antibody concentration at least as high as the
LLoQ for infants with a pre-vaccination concentration <LLoQ; and
a post-vaccination antibody concentration at least as high as the
pre-vaccination concentration for infants with a pre-vaccination
concentration LLoQ. Because of the expected decline in mater-
nally transferred pertussis antibodies between the pre- and post-
vaccination time points, a post-vaccination concentration equal
to the pre-vaccination concentration would correspond to at least
a 2-fold increase in infant-induced antibodies.
Secondary immunogenicity objectives were to assess antibody
concentrations or titers against all DTaP-HepB-IPV/Hib antigens,
seropositivity for pertussis, and serotype-specific anti-
pneumococcal antibody concentrations 1 month after the last
DTaP-HepB-IPV/Hib primary dose; and the persistence of mater-
nally transferred antibodies to all Tdap antigens in terms of con-
centrations and seroprotection/seropositivity before the first
DTaP-HepB-IPV/Hib infant primary dose.
The reactogenicity and safety of DTaP-HepB-IPV/Hib and PCV13
primary vaccination were assessed as secondary objective in terms
of the occurrence of solicited AEs, unsolicited AEs and SAEs.2.4. Statistical analyses
The sample size was based on the number of mothers enrolled
in the maternal immunization trial. The primary immunogenicity
analyses were performed on the according-to-protocol (ATP)
cohort for immunogenicity, including all eligible participants
who received at least 1 dose of the study vaccines per protocol,
complied with study procedures and intervals, were born full term
(37 weeks’ gestation) and had immunogenicity results available
for at least one of the study vaccines’ antigens. Seroprotection,
seropositivity and vaccine response rates were calculated with
exact 95% confidence intervals (CIs). Geometric mean antibody
concentrations and titers (GMCs and GMTs) were calculated with
95% CIs by taking the anti-log of the mean of the log10 concentra-
tion or titer transformations. Antibody concentrations or titers
2108 K.P. Perrett et al. / Vaccine 38 (2020) 2105–2114below the assay cut-offs were given arbitrary values of half the cut-
offs for the GMC and GMT calculations.
We also performed exploratory subgroup analyses by dose
schedule (2-dose vs 3-dose primary schedule).
The primary safety analyses were performed on the total vacci-
nated cohort (TVC), including all participants who received at least
1 study vaccine dose. Percentages of participants for whom soli-
cited or unsolicited AEs were reported were calculated with exact
95% CIs. SAEs were described in detail.
Congenital anomalies which became apparent once the mater-
nal immunization trial [24] ended were reported as pre-existing
medical condition in the present study and analyzed post-hoc.
All endpoints were descriptive. Analyses were performed using
SAS version 9.2.
3. Results
3.1. Study population
601 infants were enrolled and included in the TVC: 296 whose
mothers were randomized to receive Tdap (Tdap group) and 305
whose mothers were randomized to receive placebo (controlTotal vaccinat
N=601
Total enrolled
N=601
Tdap group
N=296
Withdrawn (n=5)
Serious adverse event (n=1)
Consent withdrawn (n=1)
Migrated/moved from study area (n=3)
Completed last visit
N=291
ATP cohort for immunogenicity
N=268
Excluded from ATP analysis (n=28)
Randomization code broken (n=1)
Study vaccine dose not administered according to 
protocol (n=2)
Vaccine temperature deviation (n=2)
Protocol violation (n=4)
Non-compliance with vaccination schedule (n=4)
Non-compliance with blood sampling schedule (n=3)
Essential serological data missing (n=12)
Fig. 2. Participant flow diagram. Abbreviations: ATP, according-to-protocol; N, number o
assigned (excluding those for whom a lower elimination code number was assigned; elim
up infant immunization trial); Tdap, reduced-antigen-content diphtheria-tetanus-acellu
infant was vaccinated outside of the study before migrating from the study site.group) during pregnancy in the maternal immunization trial. 592
infants (98.5%) completed the study and 542 (90.2%) were included
in the ATP cohort for immunogenicity (Fig. 2). Baseline character-
istics were comparable between the two groups (Table 1). Most
infants (~88%) received a 3-dose primary DTaP-HepB-IPV/Hib
schedule (mainly at 2, 4 and 6 months of age); of those who
received a 2-dose primary schedule, nearly all received their doses
at 3 and 5 months of age (Table 1).
3.2. Immunogenicity
3.2.1. Response to the DTaP-HepB-IPV/Hib primary series
The percentages of infants who reached the seroprotective
thresholds for anti-diphtheria, anti-tetanus, anti-HBs, anti-
poliovirus types 1–3 and anti-PRP 1 month post-primary vaccina-
tion were similar between groups: 100% in both groups for anti-
diphtheria and anti-tetanus, 98.5% for anti-HBs, 95.9% for
anti-poliovirus and94.5% for anti-PRP (Table 2). Vaccine response
rates against the three pertussis antigens were lower in the Tdap
than in the control group (39.6% vs 94.8% for anti-FHA, 37.5% vs
90.0% for anti-PRN and 77.1% vs 99.2% for anti-PT; Table 3). One
month post-primary vaccination, all infants in the Tdap group wereed cohort
 cohort
Control group
N=305
Withdrawn (n=4)
Consent withdrawn (n=2)
Migrated/moved from study area (n=1)
Othersa (n=1)
Completed last visit
N=301
ATP cohort for immunogenicity
N=274
Excluded from ATP analysis (n=31)
Randomization failure (n=1)
Randomization code broken (n=1)
Vaccine temperature deviation (n=2)
Protocol violation (n=3)
Non-compliance with vaccination schedule (n=7)
Non-compliance with blood sampling schedule (n=5)
Essential serological data missing (n=12)
f infants per cohort/group; n, number of infants with the specified elimination code
ination codes from the maternal immunization trial carried forward into the follow-
lar pertussis vaccine. aThis infant was withdrawn from the study at visit 2 as the
Table 1
Characteristics of participants in the total vaccinated cohort.
Tdap group
(N = 296)
Control group
(N = 305)
Mean age ± SD at vaccination dose 1,
weeks
8.7 ± 1.6 8.9 ± 1.8
Female sex, n (%) 141 (47.6) 144 (47.2)
Ethnic origin, n (%)
Whitea 269 (90.8) 288 (94.4)
Asian 5 (1.7) 0 (0.0)
African/African American 4 (1.4) 9 (3.0)
Other 18 (6.1) 8 (2.6)
DTaP-HepB-IPV/Hib schedule, n (%)
2-dose 32 (10.8) 41 (13.4)
3, 5 months 29 (9.8) 37 (12.1)
2, 4 months 3 (1.0) 4 (1.3)
3-dose 264 (89.2) 264 (86.6)
2, 4, 6 months 229 (77.4) 228 (74.8)
2, 3, 4 months 35 (11.8) 36 (11.8)
Mean weight ± SD, kg 5.3 ± 0.8 5.4 ± 0.8
Maternal age category at pregnancy
dose, n (%)
18–24 years 7 (2.4) 12 (3.9)
25–34 years 187 (63.2) 188 (61.6)
35–45 years 102 (34.5) 105 (34.4)
Gestational age category at
pregnancy dose, n (%)
27–32 weeks 174 (58.8) 179 (58.7)
33–36 weeks 121 (40.9) 126 (41.3)
>36 weeks 1 (0.3) 0 (0.0)
Abbreviations: DTaP-HepB-IPV/Hib, diphtheria-tetanus-acellular pertussis-hepati-
tis B virus-inactivated poliovirus and Haemophilus influenzae type b vaccine; N, total
number of infants per group; n (%), number (percentage) of infants in the specified
category; SD, standard deviation; Tdap, reduced-antigen-content diphtheria-teta-
nus-acellular pertussis vaccine.
a Includes White – Caucasian/European heritage (majority) and White – Arabic/
North African heritage (1 in Tdap and 3 in control group)
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lower in the Tdap than in the control group (68.5 vs 103.5 IU/mL
for anti-FHA, 60.5 vs 92.0 for anti-PRN, and 32.7 vs 54.7 for anti-
PT; Table 3). Post-primary anti-diphtheria antibody GMCs were
also lower in the Tdap than in the control group. For the other
DTaP-HepB-IPV/Hib antigens, antibody GMCs were similar
between the two groups (Table 2).Table 2
Seroprotection rates and geometric mean concentrations or titers for diphtheria, tetanus, h
(ATP cohort for immunogenicity).
Antibody (Cut-off) Tdap group
N Seroprotection, % (95% CI) GMC or GMT (95
Anti-D
(0.1 IU/mL)
264 100 (98.6–100) 1.75 (1.60–1.91)
Anti-T
(0.1 IU/mL)
266 100 (98.6–100) 2.35 (2.14–2.58)
Anti-HBs
(10 mIU/mL)
253 99.2 (97.2–99.9) 1322.8 (1116.7–1
Anti-polio 1
(8 ED50)
237 98.3 (95.7–99.5) 432.1 (351.8–530
Anti-polio 2
(8 ED50)
241 99.2 (97.0–99.9) 424.6 (342.7–526
Anti-polio 3
(8 ED50)
230 99.1 (96.9–99.9) 730.6 (596.5–894
Anti-PRP
(0.15 mg/mL) 266 95.9 (92.7–97.9) 1.86 (1.55–2.23)
(1.0 mg/mL) 64.7 (58.6–70.4)
Abbreviations: %, percentage of infants with antibody concentrations equal to or abov
interval; D, diphtheria; ED50, effective dose causing 50% effect; GMC, geometric mean
Haemophilus influenzae type b; polio 1–3, poliovirus types 1–3; (m)IU, (milli)internatio
phosphate; T, tetanus; Tdap, reduced-antigen-content diphtheria-tetanus-acellular pertu3.2.2. Response to the PCV13 primary series
One month post-primary vaccination, the percentages of infants
with serotype-specific anti-pneumococcal antibody concentrations
0.35 mg/mL were similar in both groups for each PCV13 serotype
(Table 4). Serotype-specific antibody GMCs were in the same range
in both groups for most PCV13 serotypes; minimal differences in
GMCs were observed for serotypes 4 and 19F (marginally lower
in the Tdap group) (Table 4).
3.2.3. Persistence of maternally transferred antibodies to Tdap
antigens
Before the first primary dose (i.e., at 2 or 3 months of age
depending on the schedule the infant received), more infants in
the Tdap group were seroprotected against diphtheria (82.6% in
Tdap vs 43.7% in control); against tetanus (99.2% in Tdap vs
88.9% in control); and also more were seropositive for the three
pertussis antigens (90.1%–100% in Tdap vs 34.8%–83.0% in control)
(Table 5). Antibody GMCs at the pre-primary time point in the
Tdap group were significantly higher than those in the control
group for all Tdap antigens (Table 5).
3.2.4. Subgroup analysis by dose schedule
We evaluated the immune response to the DTaP-HepB-IPV/Hib
and PCV13 primary series separately in infants who received a 2-
dose schedule (nearly all at 3 and 5 months of age) and in infants
who received a 3-dose schedule (predominantly at 2, 4 and
6 months of age). Generally, the trends we described for the overall
population were observed for both schedules (Supplementary
tables 1–3). However, interpretation of these results is limited by
the small sample size of the 2-dose subgroup.
3.3. Reactogenicity and safety
Solicited AEs were reported at similar rates in both groups, with
redness being the most commonly reported local AE at the DTaP-
HepB-IPV/Hib and PCV13 injection sites (Table 6) and irritability
the most commonly reported general AE (Table 6). Most solicited
AEs in both groups were mild or moderate. Unsolicited AEs were
reported for 54.4% and 56.7% of infants in the Tdap and control
groups, respectively, most being mild or moderate (Table 6). Upper
respiratory tract infection was the most common unsolicited AE
(Tdap: 12.2%, 95% CI: 8.7–16.4; control: 10.8%, 7.6–14.9).epatitis B, poliovirus and Hib antibodies in infants 1 month after primary vaccination
Control group
% CI) N Seroprotection, % (95% CI) GMC or GMT (95% CI)
271 100 (98.6–100) 2.75 (2.50–3.02)
271 100 (98.6–100) 2.28 (2.07–2.51)
567.0) 263 98.5 (96.2–99.6) 1339.2 (1132.8–1583.3)
.9) 244 99.2 (97.1–99.9) 489.9 (402.6–596.0)
.2) 245 95.9 (92.6–98.0) 388.4 (306.3–492.6)
.9) 237 99.6 (97.7–100) 775.6 (645.9–931.3)
271 94.5 (91.0–96.9) 1.72 (1.43–2.06)
65.3 (59.3–71.0)
e the specified seroprotection cut-offs; ATP, according-to-protocol; CI, confidence
concentration; GMT, geometric mean titer; HBs, hepatitis B surface antigen; Hib,
nal unit; N, number of infants with available results; PRP, Hib polyribosylribitol
ssis vaccine.
Table 4
Percentages of infants with pneumococcal serotype-specific antibody concentrations  0.35 mg/mL and geometric mean concentrations 1 month after primary vaccinationa (ATP
cohort for immunogenicity).
Tdap group Control group
Vaccine serotype N % 0.35 mg/mL (95% CI) GMC, mg/mL
(95% CI)
N % 0.35 mg/mL
(95% CI)
GMC, mg/mL
(95% CI)
1 232 95.7 (92.2–97.9) 1.61 (1.43–1.80) 237 95.8 (92.4–98.0) 1.92 (1.73–2.14)
3 232 74.6 (68.5–80.0) 0.54 (0.49–0.60) 237 76.4 (70.4–81.6) 0.60 (0.55–0.67)
4 232 92.2 (88.0–95.3) 1.20 (1.07–1.35) 237 96.2 (92.9–98.2) 1.56 (1.40–1.75)
5 226 88.1 (83.1–92.0) 1.09 (0.96–1.24) 234 91.5 (87.1–94.7) 1.27 (1.13–1.43)
6A 232 95.3 (91.7–97.6) 2.16 (1.89–2.47) 237 95.4 (91.8–97.7) 2.59 (2.27–2.95)
6B 232 79.7 (74.0–84.7) 1.37 (1.12–1.68) 237 84.4 (79.1–88.8) 1.44 (1.20–1.73)
7F 232 98.7 (96.3–99.7) 2.39 (2.15–2.65) 237 99.6 (97.7–100) 2.67 (2.43–2.93)
9V 232 91.4 (87.0–94.7) 1.33 (1.19–1.50) 237 95.8 (92.4–98.0) 1.64 (1.47–1.83)
14 232 98.7 (96.3–99.7) 5.70 (4.99–6.52) 237 98.3 (95.7–99.5) 6.57 (5.71–7.56)
18C 232 94.8 (91.1–97.3) 1.61 (1.42–1.82) 237 94.1 (90.3–96.7) 1.79 (1.59–2.01)
19A 232 93.1 (89.0–96.0) 1.61 (1.43–1.82) 237 95.8 (92.4–98.0) 2.01 (1.78–2.27)
19F 232 99.1 (96.9–99.9) 2.57 (2.35–2.82) 237 98.3 (95.7–99.5) 3.24 (2.92–3.60)
23F 230 79.1 (73.3–84.2) 0.86 (0.74–0.99) 236 86.0 (80.9–90.2) 1.02 (0.88–1.17)
Abbreviations: %, percentage of infants with antibody concentrations 0.35 mg/mL; ATP, according-to-protocol; CI, confidence interval; GMC, geometric mean concentration;
N, number of infants with available results; Tdap, reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine.
a 1 month after DTaP-HepB-IPV/Hib primary vaccination, which is 1 month after PCV13 primary vaccination for most infants, but 3 months after PCV13 primary vacci-
nation for those who received a 3-dose DTaP-HepB-IPV/Hib schedule at 2, 4 and 6 months of age and a 2-dose PCV13 schedule at 2 and 4 months of age.
Table 3
Vaccine response rates, seropositivity rates and geometric mean concentrations for pertussis antibodies in infants 1 month after primary vaccination (ATP cohort for
immunogenicity).
Antibody
(LLoQ)
Tdap group Control group
N Vaccine responsea, %
(95% CI)
N’ Sero-positivity, %
(95% CI)
GMC, IU/mL
(95% CI)
N Vaccine responsea, %
(95% CI)
N’ Sero-positivity, %
(95% CI)
GMC, IU/mL
(95% CI)
Anti-FHA
(2.046 IU/mL)
240 39.6
(33.4–46.1)
266 100
(98.6–100)
68.5
(63.5–73.9)
251 94.8
(91.3–97.2)
271 100
(98.6–100)
103.5
(95.6–112.1)
Anti-PRN
(2.187 IU/mL)
240 37.5
(31.4–44.0)
266 100
(98.6–100)
60.5
(54.2–67.6)
250 90.0
(85.6–93.4)
270 99.6
(98.0–100)
92.0
(81.6–103.6)
Anti-PT
(2.693 IU/mL)
240 77.1
(71.2–82.2)
266 100
(98.6–100)
32.7
(30.2–35.3)
251 99.2
(97.2–99.9)
271 100
(98.6–100)
54.7
(51.0–58.6)
Abbreviations: %, percentage of infants who mounted a vaccine response or were seropositive (antibody concentration equal to or above the specified LLoQs); ATP, according-
to-protocol; CI, confidence interval; FHA, filamentous hemagglutinin; GMC, geometric mean concentration; IU, international unit; LLoQ, lower limit of quantitation; N,
number of infants with pre- and post-vaccination results available; N’, number of infants with post-vaccination results available; PRN, pertactin; PT, pertussis toxoid; Tdap,
reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine.
a Vaccine response to FHA, PRN and PT antigens is defined as a post-vaccination antibody concentration LLoQ for infants with a pre-vaccination concentration <LLoQ; a
post-vaccination concentration at least as high as the pre-vaccination concentration for infants with a pre-vaccination concentration LLoQ.
Table 5
Seropositivity or seroprotection rates and geometric mean concentrations for diphtheria, tetanus and pertussis antibodies in infants before primary vaccination (ATP cohort for
immunogenicity).
Antibody
(LLoQ or cut-off)
Tdap group Control group
N % LLoQ or cut-off (95% CI) GMC, IU/mL (95% CI) N % LLoQ or cut-off (95% CI) GMC, IU/mL (95% CI)
Anti-D (0.1 IU/mL) 242 82.6 (77.3–87.2) 0.423 (0.354–0.506) 252 43.7 (37.4–50.0) 0.089 (0.076–0.103)
Anti-T (0.1 IU/mL) 242 99.2 (97.0–99.9) 2.152 (1.925–2.406) 253 88.9 (84.4–92.5) 0.378 (0.330–0.434)
Anti-FHA (2.046 IU/mL) 242 100 (98.5–100) 88.3 (77.7–100.4) 253 83.0 (77.8–87.4) 6.6 (5.7–7.7)
Anti-PRN (2.187 IU/mL) 242 95.5 (92.0–97.7) 70.5 (56.1–88.5) 253 59.7 (53.4–65.8) 4.5 (3.7–5.4)
Anti-PT (2.693 IU/mL) 242 90.1 (85.6–93.5) 11.9 (10.3–13.6) 253 34.8 (28.9–41.0) 2.2 (2.0–2.5)
Abbreviations: %, percentage of infants with antibody concentrations greater than or equal to the specified seroprotection cut-offs (for diphtheria and tetanus) or LLoQs (for
pertussis); ATP, according-to-protocol; CI, confidence interval; D, diphtheria; FHA, filamentous hemagglutinin; GMC, geometric mean concentration; IU, international unit;
LLoQ, lower limit of quantitation; N, number of infants with available results; PRN, pertactin; PT, pertussis toxoid; T, tetanus; Tdap, reduced-antigen-content diphtheria-
tetanus-acellular pertussis vaccine.
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group and 23 for 17 (5.6%) infants in the control group. The differ-
ence between the two groups mainly resulted from a greater num-
ber of respiratory tract and other infections reported as SAE in the
control compared to the Tdap group (15 vs 2) (Supplementary
table 4). One infant in the Tdap group was withdrawn due to SAEs(intestinal hemorrhage and milk allergy). No SAEs were deemed
related to infant vaccination and no infants died during the study.
Congenital anomalies were reported for 24 (8.1%, 95% CI: 5.3–
11.8) infants from Tdap-vaccinated mothers and 28 (9.2%, 6.2–
13.0) infants from control mothers, atrial septal defect being most
common (Tdap: 1.4%, 0.4–3.4; control: 2.6%, 1.1–5.1).
Table 6
Solicited and unsolicited adverse events after primary vaccination (total vaccinated cohort).
Adverse event Tdap group
(N = 294)
Control group
(N = 303)
n % (95% CI) n % (95% CI)
Solicited local AEs at the DTaP-HepB-IPV/Hib injection site (4 days post-vaccination)
Pain
Any 165 56.1 (50.2–61.9) 166 54.8 (49.0–60.5)
Grade 3 7 2.4 (1.0–4.8) 14 4.6 (2.5–7.6)
Redness
Any 185 62.9 (57.1–68.5) 185 61.1 (55.3–66.6)
>20 mm 10 3.4 (1.6–6.2) 14 4.6 (2.5–7.6)
Swelling
Any 137 46.6 (40.8–52.5) 138 45.5 (39.8–51.3)
>20 mm 4 1.4 (0.4–3.4) 12 4.0 (2.1–6.8)
Solicited local AEs at the PCV13 injection site (4 days post-vaccination)
Pain
Any 158 53.9 (48.0–59.7) 153 50.5 (44.7–56.3)
Grade 3 9 3.1 (1.4–5.8) 8 2.6 (1.1–5.1)
Redness
Any 163 55.6 (49.7–61.4) 170 56.1 (50.3–61.8)
>20 mm 6 2.0 (0.8–4.4) 6 2.0 (0.7–4.3)
Swelling
Any 114 38.9 (33.3–44.8) 128 42.2 (36.6–48.0)
>20 mm 8 2.7 (1.2–5.3) 11 3.6 (1.8–6.4)
Solicited general AEs (4 days post-vaccination)
Drowsiness
Any 216 73.5 (68.0–78.4) 232 76.6 (71.4–81.2)
Grade 3 14 4.8 (2.6–7.9) 16 5.3 (3.0–8.4)
Irritability
Any 255 86.7 (82.3–90.4) 257 84.8 (80.3–88.7)
Grade 3 36 12.2 (8.7–16.5) 37 12.2 (8.7–16.4)
Loss of appetite
Any 142 48.3 (42.5–54.2) 157 51.8 (46.0–57.6)
Grade 3 8 2.7 (1.2–5.3) 7 2.3 (0.9–4.7)
Fever
Any 126 42.9 (37.1–48.7) 126 41.6 (36.0–47.4)
>39.0 C 4 1.4 (0.4–3.4) 1 0.3 (0.0–1.8)
Unsolicited AEs (31 days post-vaccination)
(N = 296) (N = 305)
Any 161 54.4 (48.5–60.2) 173 56.7 (51.0–62.4)
Grade 3 15 5.1 (2.9–8.2) 18 5.9 (3.5–9.2)
Related 11 3.7 (1.9–6.6) 13 4.3 (2.3–7.2)
Abbreviations: AE, adverse event; CI, confidence interval; DTaP-HepB-IPV/Hib, diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated poliovirus and Hae-
mophilus influenzae type b vaccine; N, number of infants with at least one documented dose (for solicited AEs) or at least one administered dose (for unsolicited AEs); n/%,
number/percentage of infants for whom the specified AE was reported at least once during the follow-up periods after any of the doses; Tdap, reduced-antigen-content
diphtheria-tetanus-acellular pertussis vaccine.
Grade 3 pain was defined as crying when the limb was moved or the limb being spontaneously painful; grade 3 irritability as crying that could not be comforted or irritability
preventing normal activity; grade 3 drowsiness as drowsiness preventing normal activity; and grade 3 loss of appetite as not eating at all; unsolicited AEs were considered
grade 3 if they prevented normal activity.
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ing the findings and highlighting their clinical relevance.4. Discussion
The key rationale for pertussis immunization during pregnancy
is to protect infants too young to be vaccinated from pertussis dis-
ease and death by achieving persistent high levels of maternally
transferred pertussis antibodies in infants between birth and the
first primary immunization dose. Our study—the largest RCT to
date to investigate this—showed that administration of the
reduced-antigen-content Tdap vaccine during the third trimester
of pregnancy resulted in high levels of maternally transferred per-
tussis antibodies in infants up to the pre-primary vaccination time
point (at 2 or 3 months of age). Infants of Tdap-immunized moth-
ers presented significantly higher antibody levels for all Tdap anti-
gens before the primary series compared to infants of control
mothers. However, immunological interference was evident forpertussis (in terms of GMCs and vaccine response rates) and to a
lesser extent for diphtheria (in terms of GMC but not seroprotec-
tion rate) after the primary DTaP-HBV-IPV/Hib series in infants
born to Tdap mothers.
There was no evidence of maternally derived antibodies inter-
fering with the infant immune response to tetanus, hepatitis B,
poliovirus or Hib PRP in terms of seroprotection rates and GMCs
after the primary DTaP-HBV-IPV/Hib series. Likewise, we observed
no interference with the response to PCV13 in terms of percentages
of infants achieving the 0.35 mg/mL threshold (shown to be equiv-
alent to the threshold used for PCV licensure [33,34]). The minimal
GMC differences observed for serotypes 4 and 19F between the
two groups may be explained by the absence of statistical adjust-
ments for multiple testing.
The concept of immune interference or blunting, where mater-
nal antibodies reduce antibody generation to the infant primary
series [35,36], resulting in lower post-primary antibody concentra-
tions, is not new. Previous studies assessing the administration of
2112 K.P. Perrett et al. / Vaccine 38 (2020) 2105–2114Tdap vaccines (three- or five-component pertussis vaccines) during
pregnancy have reported significantly lower antibody responses to
one or more pertussis antigens in infants born to Tdap-vaccinated
mothers following completion of their primary series compared to
infants whose mothers had not been Tdap-vaccinated [4–8,10,20–
22]. However, this effect was not consistently observed
[4–6,10,21,22]. Similarly, several studies have shown that mater-
nally transferred diphtheria antibodies can interfere with diphthe-
ria and diphtheria-derived CRM-conjugated pneumococcal vaccine
responses to the infant primary series following Tdap immuniza-
tion during pregnancy [4,5,10,21,22,37]. In contrast to other stud-
ies [4,5,21,22] we did not see an enhancement of the immune
response to tetanus post-primary series, despite higher pre-
primary anti-tetanus GMCs in infants of Tdap-vaccinated mothers
than in controls.
Maternal antibody interference with the immune response to
infant vaccination has also been described as a natural phe-
nomenon in the absence of maternal immunization in a recent
meta-analysis of 32 clinical trials [38]. This meta-analysis showed
that pre-existing antibodies inhibit infant immune responses to
primary immunization for 20 of 21 measured antigens, and this
in the absence of maternal vaccination [38]. Two-fold higher
maternal antibody levels were estimated to result in 11% lower
post-vaccination antibody levels for PT and FHA, 22% lower for
PRN, 13% lower for tetanus and 24% lower for diphtheria [38].
Given that maternal antibodies decline rapidly over the first
months of life, mathematical modeling indicated that the inhibi-
tory effect of a 2-fold to 5-fold increase in maternal antibody con-
centrations in infants can be offset by a delay of 2.2–5.0 weeks in
starting primary vaccination [38]. A recent RCT in the Netherlands
investigated the effect of maternal Tdap immunization on pertussis
antibody responses of infants starting primary vaccination at
3 months (instead of 2 months) and still found significant blunting
[8]. In our subgroup analysis by dose schedule, nearly all infants in
the 2-dose subgroup started their primary series at 3 months of
age; interference with the pertussis response seemed to occur in
this subgroup as well; however, the small sample size of this sub-
group precludes any sound conclusions.
Importantly, the clinical relevance of the lower post-primary
antibody levels in infants from Tdap-vaccinated mothers remains
unknown, since there is no established correlate of protection for
pertussis. To date, there is no evidence that the observed immuno-
logical interference is of clinical significance as there has been no
increase in pertussis disease in infants born to Tdap-vaccinated
mothers following primary series vaccinations in the first year of
life [13,14,39]. However, this requires ongoing monitoring.
This study provides further evidence of the tolerability and
safety of DTaP-HepB-IPV/Hib and PCV13 in infants whose mothers
received Tdap vaccine during pregnancy. Rates of solicited and
unsolicited AEs were similar between groups. SAEs were not
reported more frequently in the Tdap group compared to the con-
trol group. Hence, the safety profile of DTaP-HepB-IPV/Hib and
PCV13 in infants did not change depending on whether their moth-
ers received Tdap during pregnancy.
The current study has several potential limitations. It was con-
ducted in six high-income countries, and participants of the origi-
nal study (NCT02377349) were mainly white Caucasian women
and women with low-risk pregnancies. Hence, the results may
not be generalizable to low- and middle- income countries, to
infants of other ethnic groups or infants born from high-risk preg-
nancies. In addition, analyses were descriptive with no adjustment
for multiplicity. We also did not assess the effect of breastfeeding
on antibody levels before and after the infant primary series.
Because mothers in the control group received Tdap postpartum,
antibodies to Tdap antigens might have been transferred through
breast milk to infants in the control group.A follow-up study is ongoing in the same infant cohort to inves-
tigate the effect of maternal Tdap immunization on the persistence
of antibodies induced by the primary DTaP-HepB-IPV/Hib and
PCV13 series up to 11–18 months of age and the effect on the
immune response to booster DTaP-HepB-IPV/Hib and PCV13 vacci-
nation in the child’s second year of life (NCT02853929).
5. Conclusion
Our study is the largest RCT to date providing evidence that
immunization against pertussis during pregnancy leads to high
levels of pertussis antibodies in young infants that persist until
the start of the primary immunization series. These high levels of
maternal pertussis antibodies can help to further close the suscep-
tibly gap to severe pertussis disease and death in young infants but
appear to interfere with the infant’s immune response to the pri-
mary pertussis immunization series. The clinical significance of
this interference remains unknown in the absence of a correlate
of protection. Ongoing epidemiological surveillance of the mater-
nal immunization strategy is required to further understand if
there is a clinical impact. We found no evidence of maternally
derived antibodies to Tdap antigens interfering with the infant
immune response to tetanus, hepatitis B, poliovirus or Hib PRP
and only minimal potential interference with the response to diph-
theria and two pneumococcal serotypes. The reactogenicity and
safety of DTaP-HepB-IPV/Hib and PCV13 in infants did not seem
impacted by whether their mothers received Tdap or placebo dur-
ing pregnancy.
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